Literature DB >> 11867368

The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers.

John Butterworth1, Yonggu A Lin, Richard Prielipp, Judy Bennett, Robert James.   

Abstract

UNLABELLED: Despite its long use in clinical medicine, protamine concentrations and pharmacokinetics in humans have not been reported. The occasional reoccurrence of anticoagulation after protamine reversal of heparin led us to hypothesize that protamine plasma concentrations decrease rapidly. We developed a method for the measurement of protamine in plasma. Eighteen fit volunteers gave their consent to receive 0.5 mg/kg protamine sulfate administered IV by an infusion pump over 10 min. Heart rate, mean arterial blood pressure, and cardiac output, all measured noninvasively, were recorded and blood samples obtained during and after protamine infusion. Blood plasma was subjected to solid-phase extraction and high-performance liquid chromatography. The administration of protamine was associated with no significant changes in heart rate, mean arterial blood pressure, or cardiac output. Plasma protamine concentrations decreased rapidly, becoming nondetectable within approximately 20 min. Protamine elimination differed significantly between men and women: men had significantly larger areas under the concentration versus time curve. Model-independent pharmacokinetic analysis revealed median (range) values as follows: volume of distribution at steady state, 12.3 (6.9--63.1) L; clearance, 2.2 (1.1--12.1) L/min; and t1/2, 7.4 (5.9--9.3) min. Concentration versus time plots revealed an atypical pattern inconsistent with usual exponential models. The Schwartz-Bayesian criterion identified a one-compartment Michaelis-Menten model and a two-compartment exponential model with irreversible binding as performing better than conventional one- or two-compartmental exponential models; however, performance errors were large with both Michaelis-Menten and exponential models. All models described rapid decreases in protamine blood concentrations. IMPLICATIONS: We developed a method for measurement of protamine in human blood. In volunteers, protamine concentrations decreased rapidly after administration. The rapid disappearance of protamine from the circulation, as defined by a median half-life of 7.4 min, could contribute to cases of "heparin rebound" after initial adequate reversal of heparin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867368     DOI: 10.1097/00000539-200203000-00008

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  10 in total

Review 1.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.

Authors:  Andrew J Gale; Darlene J Elias; Patricia M Averell; Paul S Teirstein; Mitchell Buck; Steven D Brown; Zinaida Polonskaya; Andrew K Udit; M G Finn
Journal:  Thromb Res       Date:  2011-04-14       Impact factor: 3.944

Review 3.  Hitting Undruggable Targets: Viewing Stabilized Peptide Development through the Lens of Quantitative Systems Pharmacology.

Authors:  Lydia Atangcho; Tejas Navaratna; Greg M Thurber
Journal:  Trends Biochem Sci       Date:  2018-12-15       Impact factor: 13.807

Review 4.  Are We Able to Dose Protamine Accurately Yet? A Review of the Protamine Conundrum.

Authors:  Patrick Hecht; Martin Besser; Florian Falter
Journal:  J Extra Corpor Technol       Date:  2020-03

5.  Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.

Authors:  Manu Thomas Kalathottukaren; Libin Abraham; Piyushkumar R Kapopara; Benjamin F L Lai; Rajesh A Shenoi; Federico I Rosell; Edward M Conway; Edward L G Pryzdial; James H Morrissey; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Blood       Date:  2016-12-29       Impact factor: 22.113

6.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

7.  Poly-Arginine Peptide-18 (R18) Reduces Brain Injury and Improves Functional Outcomes in a Nonhuman Primate Stroke Model.

Authors:  Bruno P Meloni; Yining Chen; Kathleen A Harrison; Joseph Y Nashed; David J Blacker; Samantha M South; Ryan S Anderton; Frank L Mastaglia; Andrew Winterborn; Neville W Knuckey; Douglas J Cook
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

8.  The Toxicokinetic Profile of Dex40-GTMAC3-a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin.

Authors:  Emilia Sokolowska; Bartlomiej Kalaska; Kamil Kaminski; Alicja Lewandowska; Agnieszka Blazejczyk; Joanna Wietrzyk; Irena Kasacka; Krzysztof Szczubialka; Dariusz Pawlak; Maria Nowakowska; Andrzej Mogielnicki
Journal:  Front Pharmacol       Date:  2016-03-17       Impact factor: 5.810

9.  Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models.

Authors:  Joanna Miklosz; Bartlomiej Kalaska; Piotr Podlasz; Małgorzata Chmielewska-Krzesińska; Miłosz Zajączkowski; Adam Kosiński; Dariusz Pawlak; Andrzej Mogielnicki
Journal:  Pharmaceutics       Date:  2021-03-09       Impact factor: 6.321

10.  Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection In Vitro and In Vivo.

Authors:  Jesse M Young; Amira Zine El Abidine; Ricardo A Gómez-Martinez; Virginie Bondu; Rosa T Sterk; Zurab Surviladze; Michelle A Ozbun
Journal:  Antimicrob Agents Chemother       Date:  2021-11-01       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.